NEW YORK (GenomeWeb News) – BioTrove has asked the US Securities and Exchange Commission to consent to the firm’s withdrawal of its registration statement for an initial public offering of common stock.
 
The Woburn, Mass.-based genomics research instrument developer said in its letter to the SEC yesterday that it is withdrawing the offering due to “unfavorable market conditions that would adversely affect the offering of the shares of common stock.”
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

CNBC reports that Amazon invested in the startup Grail as it sees an opportunity for its cloud computing company in genomics.

Lawrence Krauss writes at Slate that science is needed for good public policy and should not be ignored.

Researchers are working on re-making the yeast genome from scratch, according to the Associated Press.

In Cell this week: functional profiling of Plasmodium genome, a self-inactivating rabies virus, and more.